IceCure director Chan Vincent exits board role

IceCure Medical Ltd. reported that director Chan Vincent Chun Hung ceased serving on the board on August 12, 2026.

Rhea-AI Filing Summary

IceCure Medical Ltd. reported that director Chan Vincent Chun Hung ceased serving on the board on August 12, 2026. This exit Form 4 states that, following this departure, he is no longer subject to Section 16 reporting obligations for IceCure Medical Ltd., and it reports no insider transactions or holdings.

Key Figures

Director service end date: August 12, 2026 Reported purchase transactions: 0 Reported sale transactions: 0 +1 more

4 metrics

Director service end date August 12, 2026 Date Chan Vincent Chun Hung ceased to serve as a Director of IceCure Medical Ltd.

Reported purchase transactions 0 BuyCount in transaction summary for this Exit Form 4

Reported sale transactions 0 SellCount in transaction summary for this Exit Form 4

Reported derivative transactions 0 DerivativeTransactionCount in transaction summary

Key Terms

Exit Form 4, Section 16, reporting obligations, Securities Exchange Act of 1934

4 terms

Exit Form 4 regulatory

"This Exit Form 4 has been filed solely to report that the Reporting Person"

Section 16 regulatory

"no longer subject to the reporting obligations under Section 16 of the"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

reporting obligations regulatory

"and is no longer subject to the reporting obligations under Section 16"

Securities Exchange Act of 1934 regulatory

"under Section 16 of the Securities Exchange Act of 1934, as amended,"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does this Form 4 filing mean for IceCure Medical Ltd. (ICCM)?

The filing states that Chan Vincent Chun Hung ceased to serve as a director of IceCure Medical Ltd. on August 12, 2026, and therefore is no longer subject to Section 16 reporting obligations for ICCM. It reports no insider trades.

Were any shares of ICCM bought or sold in this Form 4 for Chan Vincent Chun Hung?

No. The Form 4 shows no reported transactions in IceCure Medical Ltd. securities. All transaction counts and share amounts for purchases, sales, exercises, gifts, and restructurings are listed as zero in the transaction summary.

When did Chan Vincent Chun Hung stop serving as a director of ICCM?

He ceased serving as a director of IceCure Medical Ltd. on August 12, 2026. That date is cited as the reason this is an Exit Form 4 and why he is no longer subject to Section 16 reporting obligations for ICCM.

Why is this Form 4 for ICCM described as an Exit Form 4?

It is described as an Exit Form 4 because it is filed solely to report that Chan Vincent Chun Hung ceased to serve as a Director of IceCure Medical Ltd. and thus ended his Section 16 reporting obligations for the issuer.

Is Chan Vincent Chun Hung still subject to Section 16 reporting for IceCure Medical Ltd. (ICCM)?

No. The filing explains he is no longer subject to reporting obligations under Section 16 of the Securities Exchange Act of 1934 with respect to IceCure Medical Ltd., following his departure from the board on August 12, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/17/2026 - 08:15 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chan Vincent Chun Hung

(Last) (First) (Middle)

7 HA'ESHEL ST., PO BOX 3163

(Street)

CAESAREA 3079504

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
IceCure Medical Ltd. [ ICCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Exit Form 4 has been filed solely to report that the Reporting Person ceased to serve as a Director of IceCure Medical Ltd (the "Issuer") on August 12, 2026 and is no longer subject to the reporting obligations under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to the Issuer.

	/s/ Vincent Chun Hung Chan	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)